These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
830 related articles for article (PubMed ID: 32900796)
1. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796 [TBL] [Abstract][Full Text] [Related]
3. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255 [TBL] [Abstract][Full Text] [Related]
4. Activity and resistance to KRAS Ye W; Lu X; Qiao Y; Ou WB Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697 [TBL] [Abstract][Full Text] [Related]
5. Clinical Acquired Resistance to KRAS Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136 [TBL] [Abstract][Full Text] [Related]
6. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306 [TBL] [Abstract][Full Text] [Related]
7. Targeting PI3Kα overcomes resistance to KRas Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339 [TBL] [Abstract][Full Text] [Related]
8. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319 [TBL] [Abstract][Full Text] [Related]
9. EGFR Blockade Reverts Resistance to KRAS Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388 [TBL] [Abstract][Full Text] [Related]
10. HER2 mediates clinical resistance to the KRAS Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459 [TBL] [Abstract][Full Text] [Related]
11. Acquired Resistance to KRAS Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704 [TBL] [Abstract][Full Text] [Related]
12. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer. Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115 [TBL] [Abstract][Full Text] [Related]
13. The KRAS-G12C inhibitor: activity and resistance. Liu J; Kang R; Tang D Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232 [TBL] [Abstract][Full Text] [Related]
17. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020 [TBL] [Abstract][Full Text] [Related]
18. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
19. Amplification of Wild-type Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474 [TBL] [Abstract][Full Text] [Related]